Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM
Status:
Completed
Trial end date:
2017-04-08
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter phase II trial designed to determine efficacy and safety
of a combination chemotherapy consisting of Bendamustine + Dexamethasone + Thalidomide in
patients with multiple myeloma (MM) after treatment with lenalidomide and bortezomib or which
are ineligible to one of these drugs.